User profiles for VANESSA INNAO
Vanessa InnaoUniversity of Messina Verified email at unime.it Cited by 1726 |
Anticancer activity of curcumin and its analogues: preclinical and clinical studies
Curcumin has been shown to have a wide variety of therapeutic effects, ranging from anti-inflammatory,
chemopreventive, anti-proliferative, and anti-metastatic. This review provides an …
chemopreventive, anti-proliferative, and anti-metastatic. This review provides an …
[HTML][HTML] Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma
Multiple myeloma (MM) is typically exemplified by a desynchronized cytokine system with
increased levels of inflammatory cytokines. We focused on the contrast between inflammatory …
increased levels of inflammatory cytokines. We focused on the contrast between inflammatory …
[HTML][HTML] Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies
In October 2019, a viral infectious disease appeared in the city of Wuhan in China. A new
betacoronavirus, SARS-CoV-2, has been recognized as the responsible pathogen in this …
betacoronavirus, SARS-CoV-2, has been recognized as the responsible pathogen in this …
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma
…, M Zappalą, S Grasso, C Musolino, V Innao… - Pharmacology & …, 2018 - Elsevier
The ubiquitin-proteasome system (UPS) is the major non-lysosomal proteolytic system for
the degradation of abnormal or damaged proteins no longer required. The proteasome is …
the degradation of abnormal or damaged proteins no longer required. The proteasome is …
The cancer stem cell hypothesis: a guide to potential molecular targets
Common cancer theories hold that tumor is an uncontrolled somatic cell proliferation caused
by the progressive addition of random mutations in critical genes that control cell growth. …
by the progressive addition of random mutations in critical genes that control cell growth. …
New orally active proteasome inhibitors in multiple myeloma
Bortezomib is the first proteasome inhibitor approved for the therapy of multiple myeloma (MM).
Although Bortezomib has renovated the treatment of MM, a considerable proportion of …
Although Bortezomib has renovated the treatment of MM, a considerable proportion of …
Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw
…, M Mania, A D'Ascola, A Avenoso, V Innao… - Annals of …, 2018 - Springer
Bisphosphonates are formidable inhibitors of osteoclast-mediated bone resorption employed
for therapy of multiple myeloma (MM) subjects with osteolytic lesions. Osteonecrosis of the …
for therapy of multiple myeloma (MM) subjects with osteolytic lesions. Osteonecrosis of the …
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma
…, A Alonci, S Russo, B Greve, V Innao… - European journal of …, 2013 - Wiley Online Library
Despite recent treatments, such as bortezomib, thalidomide, and lenalidomide, therapy of
multiple myeloma ( MM ) is limited, and MM remains an incurable disease associated with high …
multiple myeloma ( MM ) is limited, and MM remains an incurable disease associated with high …
Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells
Hematological malignancies frequently express cancer-associated antigens that are shared
with normal cells. Such tumor cells elude the host immune system because several T cells …
with normal cells. Such tumor cells elude the host immune system because several T cells …
[HTML][HTML] Formaldehyde exposure and acute myeloid leukemia: a review of the literature
Background and objective: The aim of the present study was to evaluate associations between
cumulative and peak formaldehyde exposure and occurrence of acute myeloid leukemia. …
cumulative and peak formaldehyde exposure and occurrence of acute myeloid leukemia. …